GGT-100 Vector achieves precision targeting of pulmonary artery smooth muscle cells in non-human primates
GlueGene Therapeutics (CEO Moon-soo Lee), a precision-guided gene delivery vehicle developer, announced on the 14th that it presented the primate targeting performance of its Adeno-Associated Virus (AAV) vectors at the American Society of Gene & Cell Therapy (ASGCT 2026) on May 13.
ASGCT is the world’s largest global conference in the gene therapy sector, serving as a premier venue for sharing academic achievements and facilitating technology marketing.
“As of last April, a total of nine AAV-based gene therapies, including ‘Otameni,’ have received approval from the U.S. Food and Drug Administration (FDA),” a company official stated. “This reinforces AAV’s position as the industry standard for gene delivery.”
As drug development progresses through preclinical and clinical stages, developers must overcome hurdles related to safety, efficacy, and productivity. The company explained that primate targeting is recognized as an essential process in the clinical translation of gene therapies, as it helps predict the efficacy and safety of candidates in humans.
GlueGene Therapeutics previously reported the targeting performance of its p2CV vector—which specifically delivers to pulmonary artery smooth muscle cells—in the journal Nature Biomedical Engineering in 2025. This latest announcement proves that the vector is capable of precision targeting of smooth muscle cells in primates as well.
“Proving vector targeting in primates significantly increases the probability of success in therapeutic development,” the official added. “Due to its significance, this achievement was selected for an oral presentation in the ‘AAV Capsid Engineering’ session, one of the conference’s major tracks.”
Moon-soo Lee, CEO of GlueGene Therapeutics, commented, “This presentation will serve as a catalyst not only for networking with potential co-development partners but also for exploring indication expansion into other diseases that require precise targeting of smooth muscle cells.”
